Th1/Th2 cytokines in psoriasis

Iranian Journal of Public Health

Volumn 36, Issue 2, 2007, Pages 87-91

  Jadali, Z ^a   Izad, M ^b   Eslami, M B ^a   Mansouri, P ^c   Safari, R ^c   Bayatian, P ^a   Mirshafiey, A ^a   Salehi Nodeh, A R ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cytokines; Psoriasis; T cell

Indexed keywords

EID: 34848869384     PISSN: 22516085     EISSN: 22516093     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Nickoloff BJ, Nestle FO (2004). Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest, 113: 1664-75.
2. Schon MP, Boehncke WM (2005). Psoriasis. N Engl J Med, 352: 1899-912.
3. Bowcock AM, Cookson WO (2004). The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum Mol Genet, 13: R43-55.
4. Ortonne JP (1999). Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol, 140(Suppl 54): 1-7.
5. Krueger JG, Bowcock A (2005). Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis, 64(Suppl 2): ii30-6.
6. Prinz JC (2003). The role of T cells in psoriasis. J Eur Acad Dermatol Venereol, 17: 257-70.
7. Kelso A (2000). Cytokines and their receptors: An overview. Ther Drug Monit, 22: 40-3.
8. Vollmer S, Menssen A, Trommler P, Schendel D, Prinz JC (1994). T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur J Immunol, 24: 2377-82.
9. Bonifati C, Ameglio F (1999). Cytokines in psoriasis. Int J Dermatol, 38: 241-51.
10. Szegedi A, Aleksza M, Gonda A, Irinyi B, Sipka S, Hunyadi J, et al. (2003). Elevated rate of Thelper1 (T(H)1) lymphocytes and serum IFN-gamma levels in psoriatic patients. Immunol Lett, 86: 277-80.
11. Jacob SE, Nassiri M, Kerdel FA, Vincek V (2003). Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity. Mediators Inflamm, 12: 309-13.
12. Fredriksson T, Pettersson U (1978). Severe psoriasis-oral therapy with a new retinoid. Dermatologica, 157: 238-44.
13. Nickoloff BJ (1991). The cytokine network in psoriasis. Arch Dermatol, 127: 871-84.
14. Del Prete G (1998). The concept of type-1 and type-2 helper T cells and their cytokines in humans. Int Rev Immunol, 16: 427-55.
15. Muller B, Gimsa U, Mitchison NA, Radbruch A, Sieper J, Yin Z (1998). Modulating the Th1/Th2 balance in inflammatory arthritis. Springer Semin Immunopathol, 20: 181-96.
16. Karlsson MG, Ludvigsson J (2000). The ABBOS-peptide from bovine serum albumin causes an IFN-gamma and IL-4 mRNA response in lymphocytes from children with recent onset of type 1 diabetes. Diabetes Res Clin Pract, 47: 199-207.
17. Phenekos C, Vryonidou A, Gritzapis AD, Baxevanis CN, Goula M, Papamichail M (2004). Th1 and Th2 serum cytokine profiles characterize patients with Hashimoto's thyroiditis (Th1) and Graves' disease (Th2). Neuroimmunomodulation, 11: 209-13.
18. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG (1999). The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol, 113: 752-59.
19. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ (1993). The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol, 101: 701-5.
20. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, et al. (1994). T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol, 102: 145-9.
21. Cooper KD, Hammerberg C, Baadsgaard O, Elder JT, Chan LS, Sauder DN, et al. (1990). IL-1 activity is reduced in psoriatic skin. Decreased IL-1 alpha and increased nonfunctional IL-1 beta. J Immunol, 144: 4593-603.
22. Romero LI, Ikejima T, Pincus SH (1989). In situ localization of interleukin-1 in normal and psoriatic skin. J Invest Dermatol, 93: 518-22.
23. Takematsu H, Ohta H, Tagami H (1989). Absence of tumor necrosis factor-alpha in suction blister fluids and stratum corneum from patients with psoriasis. Arch Dermatol Res, 281: 398-400.
24. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD(1994). Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol, 96: 146-51.